The approval of Novo Nordisk’s diabetes drug Victoza has led to an unintended benefit for a competitor.
VIVUS’ Qnexa Shows Promise For Diabetics
VIVUS, a pharmaceutical company specializing in products to treat sexual function, announced that their experimental obesity drug Qnexa was shown to improve blood sugar control in patients with type 2 diabetes.
